Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS
Magnetic resonance spectroscopic imaging has demonstrated cerebral N-acetylaspartate decreases as a potential biomarker of neuronal loss, but most studies have examined only a small region of interest. The Metabolite Imaging and Data Analysis System permitted whole-brain study and linked NAA decreases within the corticospinal tract to disability in ALS.
See p. 610
From editorialists Brodtmann & Kiernan: “…these recent neuroimaging findings outline a model of ALS as a ‘systems degeneration,’ bringing us one step closer to an understanding of how ALS disease spread may occur.”
See p. 606
ALS dysphagia pathophysiology: Differential botulinum toxin response
The improvement after botulinum toxin type A observed in patients with isolated upper esophageal sphincter dysfunction suggests a different ALS pathophysiology of dysphagia that responds better to this treatment. Botulinum toxin type A may be an alternative to treatment with percutaneous endoscopic gastrostomy (PEG) and may prolong PEG-free time.
See p. 616
Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD
The authors assessed disease progression in 129 patients with newly diagnosed PD. The presence of levodopa-nonresponsive motor symptoms and cognitive dysfunction at the time of diagnosis were the main determinants of disability, showing the importance of extra-nigrostriatal pathology in PD.
See p. 627
Functional disturbance of the locomotor network in progressive supranuclear palsy
[18F]-FDG-PET scans were performed in 12 patients with progressive supranuclear palsy (PSP) and 12 controls during walking and at rest. Gait impairment in PSP was associated with dysfunction of the indirect, modulatory prefrontal–subthalamic–pedunculopontine loop of locomotor control; activity in the direct, stereotyped locomotor loop to the spinal cord with rhythmic cerebellar drive was increased.
See p. 634
A randomized controlled trial of intranasal ketamine in migraine with prolonged aura
This study investigated the effect of 25 mg intranasal ketamine on migraine with prolonged aura in 30 migraineurs using 2 mg intranasal midazolam as an active control, with data from 3 episodes recorded. Intranasal ketamine was effective in reducing aura severity in patients with migraine with prolonged aura.
See p. 642
Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration
The authors quantified the cerebral atrophy rates and acceleration rates using 0-, 6-, 12-, 18-, 24- and 36-month MRI scans in subjects with mild cognitive impairment, subjects with mild Alzheimer disease (AD), and healthy controls. The small acceleration rates suggested a long period of transition to the pathologic losses seen in clinical AD.
See p. 648
CONTEMPORARY ISSUES
Teleneurology applications: Report of the Telemedicine Work Group of the American Academy of Neurology
This article discusses teleneurology from the patient and provider perspectives; also discussed are the experience from the military, barriers to growth of teleneurology, and the importance of support from the American Academy of Neurology. Teleneurology provides opportunities for neurologists and patients to improve care and enhance neurologic practice.
See p. 670
Footnotes
NB: “A keratoma horn following deep brain stimulation,” see p. 688. To check out other NeuroImages, point your browser to www.neurology.org.
- © 2013 American Academy of Neurology
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.